Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04712994
Other study ID # STUDY00008392
Secondary ID R01HD094630R01AI
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2021
Est. completion date January 31, 2022

Study information

Verified date August 2023
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study tests strategies for improving PrEP implementation in maternal and child health clinics using a difference-in-difference approach.


Description:

This study aims to improve integrated delivery of PrEP to women seeking health services in maternal and child health clinics by piloting and evaluating four strategies or bundles of strategies for optimized PrEP delivery. Strategies to be tested include a pre-developed package of strategies (video counseling, HIV self-testing, and optimized delivery).


Recruitment information / eligibility

Status Completed
Enrollment 1958
Est. completion date January 31, 2022
Est. primary completion date November 30, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria: - Women receiving Maternal and Child Health (MCH) services HCW participating in satisfaction surveys Exclusion Criteria: - Unwilling or unable to provide informed consent

Study Design


Intervention

Other:
PrEP Optimization Interventions
A bundle of strategies (video-based PrEP counselling, HIV Self-Testing [HIVST] for women undergoing repeat HIV testing, and optimized PrEP delivery and prescription processes) will be implemented in the intervention group.

Locations

Country Name City State
Kenya Kendu Sub-District Hospital Homa Bay
Kenya Ober Health Center Homa Bay
Kenya Masogo Sub-County Hospital Kisumu
Kenya Nyahera Sub Sub County Hospital Kisumu
Kenya Bondo County Referral Hospital Siaya
Kenya Madiany Sub County Hospital Siaya
Kenya Malanga Health Center Siaya
Kenya Uyawi Sub County Hospital Siaya

Sponsors (4)

Lead Sponsor Collaborator
University of Washington Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in PrEP penetration Proportion of women who are screened for PrEP / total women receiving antenatal or postnatal services 6 months
Primary Change in PrEP fidelity Proportion of women who receive all PrEP specific steps in a visit: HIV testing, HIV risk screening, PrEP counseling 6 months
Primary Change in timeliness of services Time (minutes) spent receiving services from health care works 6 months
Primary Change in time waiting Time (minutes) spent waiting to receive services 6 months
Primary Change in HCW acceptability Average Acceptability of Intervention Measures (AIM) score, 1 (Completely disagree) to 5 (Completely Agree) Likert scale 6 months
Primary Change in health care worker (HCW) appropriateness Average Intervention Appropriateness Measure (IAM) score, 1 (Completely disagree) to 5 (Completely Agree) Likert scale 6 months
Primary Change in client satisfaction Exit survey of clients to assess their satisfaction with services received at the facility, 1 (worse) to 4 (better) scale 6 months
Secondary Change in PrEP uptake Proportion of women who accept PrEP among those offered 6 months
Secondary Change in PrEP continuation Proportion of women who present for a refill among those initially prescribed PrEP 6 months
Secondary Change in PrEP adherence Proportion of women who have >80 percent adherence to PrEP by pill count among those initially prescribed PrEP 6 months
Secondary Change in PrEP efficiency Patient flow mapping to identify more efficient client flows with fewer transitions between physical spaces and providers 6 months
Secondary Change client PrEP knowledge Average score of PrEP information questions based on content covered in counseling sessions 6 months
See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2